Tumor-associated and tumor-specific antigen–peptide–major histocompatibility complex (MHC) complex

Tumor-associated and tumor-specific antigens presented by peptide–MHC complexes refer to short antigenic peptides derived from proteins selectively or uniquely expressed in tumor cells, which are bound and displayed on cell surfaces by major histocompatibility complex (MHC) molecules. These peptide–MHC complexes are recognized by T cell receptors on cytotoxic CD8+ or helper CD4+ T cells, triggering immune responses against tumor cells[1][2][4][5]. The specific combination of a tumor antigenic peptide and a particular MHC allele determines the immunogenicity and specificity of the anti-tumor T cell response. Because defects in antigen processing/presentation are a common tumor immune evasion mechanism, these complexes are fundamental targets for next-generation cancer immunotherapies, including engineered TCRs and antibody-like fusion proteins targeting tumor-selective peptide–MHC complexes[3][4]. Clarification: This query combines an *antigenic complex* and not a single defined molecule or gene. This “target” is a functional immunological entity—defined by the complex of a tumor antigenic peptide, a specific MHC allele, and the presenting cell. This entry therefore does not represent a traditional "molecular target" like a defined receptor, enzyme, or gene product (e.g., “Epidermal growth factor receptor” or “MHC class I molecule”). This makes it *overly broad and somewhat ambiguous* as a “target” for strict biochemical/pharmacological information[3][4]. If structured data for a database, this should map to more specific peptide–MHC allele complexes, or to MHC class I (HLA-A, -B, -C) and class II (HLA-DR, -DP, -DQ) molecules presenting validated tumor-associated antigens. Summary: - This entry covers a *class/function* (“peptide–MHC complex presenting tumor antigen”) and not a unique, well-defined molecule. - It is a valid therapeutic target in cancer immunotherapy and T cell therapy but *is not a standard molecular entity* and therefore should be flagged as overbroad and potentially requiring refinement for structured data.

Other names

Tumor antigen–peptide–MHC complexTumor peptide–MHC complexCancer antigen–MHC complex

Targeted immune recognition by cytotoxic T lymphocytes (CTLs) of tumor antigen–peptide–MHC complexes[3][4] Recruitment/activation of T cells to kill tumor cells displaying these complexes[3]